Drugs / D-0120
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05360628 | Nov 2021 → Feb 2022 | — | InventisBio Co., Ltd | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT04097405 | Sep 2019 → Mar 2020 | — | InventisBio Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03291782 | Sep 2017 → Apr 2018 | gout | InventisBio Co., Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03923868 | Apr 2019 → Dec 2021 | gout | InventisBio Co., Ltd | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05665699 | Apr 2023 → Jul 2025 | gout | InventisBio Co., Ltd | Completed | No outcome recorded |
| Phase 2 | NCT05504083 | Sep 2022 → May 2024 | — | InventisBio Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | D-0120 | “take D-0120 dose 1 orally during the treatment period.” NCT05504083 ↗ |
| Route | Oral | “oral, single dose” NCT03291782 ↗ |